CSTONE PHARMA-B Shares Surge Over 9% Following FTSE China Inclusion and Progress in Triple Antibody Trial

Stock News03-06

CSTONE PHARMA-B (02616) rose more than 9% again. At the time of writing, the stock was up 9.18% to HK$7.02, with a turnover of HK$70.8136 million. On the news front, according to the semi-annual review adjustments of the FTSE Global Equity Index Series (FTSE GEIS) released by the global authoritative index compiler FTSE Russell, CSTONE PHARMA-B has been successfully included as a constituent of the FTSE China Small Cap Index. The relevant adjustments will officially take effect after the market close on March 20, 2026. Guoyuan International noted that the company's PD-1/VEGF/CTLA-4 trispecific antibody demonstrates excellent safety and efficacy data. A global multi-center Phase II clinical study is currently underway, with 200 patients already enrolled. As clinical data begins to be released progressively starting in March this year, a significant business development deal is anticipated.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135152718?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-06 11:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135152718","market":"sg","top_or_hot":-1,"title":"CSTONE PHARMA-B Shares Surge Over 9% Following FTSE China Inclusion and Progress in Triple Antibody Trial","media":"Stock News","content":"<p>CSTONE PHARMA-B (02616) rose more than 9% again. At the time of writing, the stock was up 9.18% to HK$7.02, with a turnover of HK$70.8136 million. On the news front, according to the semi-annual review adjustments of the FTSE Global Equity Index Series (FTSE GEIS) released by the global authoritative index compiler FTSE Russell, CSTONE PHARMA-B has been successfully included as a constituent of the FTSE China Small Cap Index. The relevant adjustments will officially take effect after the market close on March 20, 2026. Guoyuan International noted that the company's PD-1/VEGF/CTLA-4 trispecific antibody demonstrates excellent safety and efficacy data. A global multi-center Phase II clinical study is currently underway, with 200 patients already enrolled. As clinical data begins to be released progressively starting in March this year, a significant business development deal is anticipated.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSTONE PHARMA-B Shares Surge Over 9% Following FTSE China Inclusion and Progress in Triple Antibody Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSTONE PHARMA-B Shares Surge Over 9% Following FTSE China Inclusion and Progress in Triple Antibody Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-03-06 11:59</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CSTONE PHARMA-B (02616) rose more than 9% again. At the time of writing, the stock was up 9.18% to HK$7.02, with a turnover of HK$70.8136 million. On the news front, according to the semi-annual review adjustments of the FTSE Global Equity Index Series (FTSE GEIS) released by the global authoritative index compiler FTSE Russell, CSTONE PHARMA-B has been successfully included as a constituent of the FTSE China Small Cap Index. The relevant adjustments will officially take effect after the market close on March 20, 2026. Guoyuan International noted that the company's PD-1/VEGF/CTLA-4 trispecific antibody demonstrates excellent safety and efficacy data. A global multi-center Phase II clinical study is currently underway, with 200 patients already enrolled. As clinical data begins to be released progressively starting in March this year, a significant business development deal is anticipated.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IWO","symbol_name":"罗素2000成长股指数ETF","start_time":0,"source_url":"","article_id":"1135152718","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135152718","pubTimestamp":1772769544,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CSTONE PHARMA-B (02616) rose more than 9% again. At the time of writing, the stock was up 9.18% to HK$7.02, with a turnover of HK$70.8136 million. On the news front, according to the semi-annual...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IWO":"罗素2000成长股指数ETF","BK1161":"生物科技","TZA":"罗素2000指数三倍做空ETF","BK4534":"瑞士信贷持仓","BK1574":"生物医药B类股","UWM":"罗素2000指数ETF两倍做多","RWM":"罗素2000指数反向ETF","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","02616":"基石药业-B","BK4588":"碎股","BK4535":"淡马锡持仓","TWM":"罗素2000指数两倍做空ETF","IWN":"罗素2000价值股指数ETF-iShares","SRTY":"罗素2000指数三倍做空ETF-ProShares","BK4614":"Manus概念股","BK4550":"红杉资本持仓"},"translate_title":"基石药业-B股在富时中国纳入且三抗试验取得进展后飙升逾9%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TWM":1,"MNQmain":1,"IWO":1,"IWN":1,"SRTY":1,"02616":1,"TZA":1,"UWM":1,"RWM":1},"content_text":"CSTONE PHARMA-B (02616) rose more than 9% again. At the time of writing, the stock was up 9.18% to HK$7.02, with a turnover of HK$70.8136 million. On the news front, according to the semi-annual review adjustments of the FTSE Global Equity Index Series (FTSE GEIS) released by the global authoritative index compiler FTSE Russell, CSTONE PHARMA-B has been successfully included as a constituent of the FTSE China Small Cap Index. The relevant adjustments will officially take effect after the market close on March 20, 2026. Guoyuan International noted that the company's PD-1/VEGF/CTLA-4 trispecific antibody demonstrates excellent safety and efficacy data. A global multi-center Phase II clinical study is currently underway, with 200 patients already enrolled. As clinical data begins to be released progressively starting in March this year, a significant business development deal is anticipated.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135152718","isCrawlerRequest":true}